Chairs: TBC, TBC

EDC01.1 Pilocytic astrocytoma
TBC, -

EDC01.2 Malignant meningioma (incl. radionuclide therapy)
Emeline Tabouret, France

EDC01.3 Pineal tumors
TBC, -

EDC01.4 Glioneuronal tumors (incl. DNET)
Roberta Ruda, Italy

Chairs: TBC, TBC

EDN01.1 First principles in neuro rehab
TBC, -

EDN01.2 Rehabilitation in People Living with brain tumours: A Narrative Review of the Literature
Anna Zanotto, United States

EDN01.3 Professionals Prehabilitation service in Neuro-Oncology
TBC, -

EDN01.4 Tessa Jowell Roadmap for rehabilitation
Andrew Wright, United Kingdom

Chairs: TBC, TBC

EDB02.1 Oncogenic drivers in glioma biology
Rainer Glass, Germany

EDB02.2 Epigenetic drivers in glioma biology
TBC, -

EDB02.3 DNA repair mechanisms in brain tumor biology and therapy
Susan Short, United Kingdom

Chairs: TBC, TBC

EDC02.1 Genetics in brain tumors and hereditary syndromes
TBC, -

EDC02.2 Pathology: Updates after WHO 2021
Laetitia Lebrun, Belgium

EDC02.3 Trial design in today's neuro-oncology
TBC, -

Chairs: TBC, TBC

EDN02.1 Dose-Dependent Effects of Radiotherapy on Brain Changes: A Neuroimaging Perspective
Joost Verhoff, Netherlands

EDN02.2 How tumour location, molecular markers and treatment relate to functional connectivity and cognitive functioning of brain tumour patients
Linda Douw, Netherlands

EDN02.3 The multifaced role of personality and its pathoplastic effect on the presentation and treatment of behavioral alterations in people with gliomas
Loredana Dinapoli, Italy

Chairs: TBC

EDB03.1 Advanced in vitro models
Anna Golebiewska, Luxembourg

EDB03.2 Modelling therapeutic stress in brain metastases
Lauritz Miarka, Germany

EDB03.3 Modelling surgical resection in glioma
Aurelie Tchoghandjian, France

EDB03.4 What can in vivo reporters tell us
Gaetano Gargiulo, Germany

EDB03.5 Modelling neuronal crosstalk and intercellular transfer
Hrvoje Miletic, Norway

Chairs: TBC

EDC03.1 Supramarginal resection in diffuse glioma
Philipp Karschnia, Germany

EDC03.2 Vorasidenib - lesson's learned
Marjolein Geurts, Netherlands

EDC03.3 Other targeted therapies in glioma
Mehdi Touat, France

EDC03.4 How to diagnose pseudoprogression
Laurien de Roeck, Belgium

EDC03.5 How to manage pseudoprogression
Dieta Brandsma, Netherlands

Chairs: TBC

EDN03.1 A perspective from COGNO: brain tumour trials in Australia
Eng-Siew Koh, Australia

EDN03.2 Supportive care trials for carers and patients with high-grade brain tumours
Laurie Minns, United States

EDN03.3 Costing models for Palliative care in Neuro-Oncology
Esme Van Der Poort, Netherlands

EDN03.4 Be Special implementation project
Emma Nicklin, United Kingdom

EDN03.5 Advance care planning and decision-making within trials for glioma patients
Ai Chikada, Japan

Chairs: TBC

EDB04.1 Cell of origin in medulloblastoma/pediatric brain tumors
TBC, -

EDB04.2 Preclinical models of pediatric brain tumors
Marcel Kool, Netherlands

EDB04.3 Molecular mechanisms of transformation in HGG and ependymoma
Maria Vinci, Italy

EDB04.4 Oncogen induced senescence in low grade glioma
Till Milde, Germany

Chairs: TBC

EDC04.1 What is the role of the neurosurgeon in the targeted therapy era?
Alireza Mansouri, United States

EDC04.2 Radiation therapy developments in BM
Paola Jablonska, Spain

EDC04.3 Development in systemic therapies in BM
Anna Berghoff, Austria

EDC04.4 Development in treating leptomeningeal Metastases
Adrienne Boire, United States

Chairs: TBC

EDB03.1 A collective insight into nurses and AHPs working in neuro-oncology: barriers to career progression and potential solutions
Florien Boele, United Kingdom

EDB02.2 Panellist 1
Karin Piil, Denmark

EDB02.3 Panellist 2
TBC, -

EDB02.4 Panellist 3
Martin Klein, Netherlands

Chairs: TBC

EDB05.1 Explainable AI and brain tumor classification
TBC, -

EDB05.2 AI in high content preclinical imaging
TBC, -

EDB05.3 AI for drug repurposing
Olivier Gevaert, United States

Chairs: TBC

Caroline Hertler, Switzerland
Johan Koekkoek, Netherlands
Sara Melhuish, United Kingdom
Lena Rosenlund, Sweden
Isabelle Ryden, Sweden

Chairs: TBC, TBC

PC01.1 Proton therapy in IDH-mutant - Pro
Danielle Eekers, Netherlands

PC01.2 Proton therapy in IDH-mutant - Con
Giuseppe Minniti, Italy

PC01.3 Systemic vs. local treatment in active breast cancer brain metastasis: Systemic treatment
Rupert Bartsch, Austria

PC01.4 Systemic vs. local treatment in active breast cancer brain metastasis: Local treatment
Elena Clerici, Italy

PC01.5 Surgical resection/biopsy vs. imaging-based diagnosis of radionecrosis - Pro surgery
TBC, -

PC01.6 Surgical resection/biopsy vs. imaging-based diagnosis of radionecrosis - Pro imaging
TBC, -

Chairs: TBC, TBC

OS01.1 Immune targeting of axonal guidance dependencies
Sheila Singh, United Kingdom

OS01.2 Multi-valent CAR T cells targeting glioblastoma
Denis Migliorini, Switzerland

OS01.3 Metabolically armored CAR T cell therapeutic approaches and interaction with macrophages
Leila Akkari, Netherlands

OS01.4 Tertiary Lymphoid Structures in Gliomas - When immune cells come together
Katharina Imkeller, Germany

Chairs: Anneli Ozanne, TBC

OS02.1 The situation of Brain Tumor Management in European Outermost Regions
Julio Plata-Bello, Spain

OS02.2 Ethnicity in neuro-oncology research: How are we doing and how can we do better?
TBC, -

OS02.3 Access to psychosocial support for people with brain tumor and family members: Healthcare professional perspectives (to also bring in COGNO perspective)
TBC, -

OS02.4 Quantifying and describing personal social networks in glioblastoma
TBC, -